Navigation Links
FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
Date:4/9/2012

ATLANTA, Ga., April 9, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., is pleased to announce that the company will be exhibiting at the inaugural Atlanta Clinical Cardiology Update (CCU), presented by the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University, April 13-14, 2012. The inaugural meeting will provide a new, needs-based and convenient forum for knowledge exchange between general and sub-specialist cardiologists across the spectrum of cardiovascular disease.  

FirstMark will showcase its new cardiovascular test PREvent at the meeting. PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction in patients with suspected or confirmed, insignificant or significant stable CAD. The test is an exciting development in cardiovascular medicine, providing a simple solution for the huge unmet need of assessing CAD patients risk of near term myocardial infarction.

"One of the goals of the inaugural Atlanta CCU meeting is to give attendees the opportunity to catch up on recent clinical trials that are likely to influence practice, presented at conferences such as the American Heart Association and American College of Cardiology Scientific Sessions. The clinical trial for PREvent, was conducted at Emory University and presented at both of these conferences in oral Poster Presentations," said Thomas Silberg, President and CEO of GenWay Biotech. "The final data is quite remarkable, and we are excited for the opportunity to once again highlight the study and present the test."

About PREvent
PREvent provides superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal. The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.

For additional information, please visit FirstMarkPREvent.com.

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development
and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area.



Media Contact: Deborah Moore GenWay Biotech, 858-458-0866, dmoore@genawaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
2. BIO-key(R) International Exhibiting at AABB TXPO
3. BIO-key(R) International Exhibiting at AABB TXPO
4. Exposure to young triggers new neuron creation in females exhibiting maternal behavior
5. Penn presents inaugural symposium on applied mathematics and computational science
6. Massague honored with inaugural AACR Distinguished Leadership Award in Breast Cancer Research
7. Easton honored with inaugural AACR Outstanding Investigator Award in Breast Cancer Research
8. George M. Whitesides receives inaugural Dreyfus prize in the chemical sciences
9. George Whitesides accepts inaugural Dreyfus Prize in the Chemical Sciences
10. International AIDS Society announces inaugural recipients of innovative HIV research awards
11. Inaugural Herbert A. Fleisch ESCEO-IOF Medal is awarded to Professor Gerard Karsenty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from ... and ProText™, making them the first Wharton’s jelly allografts to be assigned a Q ... company’s solutions are the first Wharton’s jelly allograft product to be recognized as a ...
(Date:7/31/2020)... ... 2020 , ... Justin Zamirowski to lead upcoming launches of ... on Type 2 diabetes and associated comorbidities. , Justin brings over 20 years ... As Chief Commercial Officer, Justin will lead Better Therapeutics’ efforts in ...
(Date:7/18/2020)... , ... July 17, 2020 , ... Commercial launch readiness ... pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will ... price pressure is not going away and capturing full value from every product launch ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a ... of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. ... lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine ...
(Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT ... Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: ... hosted an elite awards program, highlighting outstanding examples of how technology innovations and ...
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to competitively procured purchasing contracts to its membership, recently named BioFit Engineered ... members with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and ...
(Date:6/28/2020)... LAGUNA NIGUEL, Calif. (PRWEB) , ... June 25, 2020 , ... ... today announced the launch of Safe Space™ for businesses of all types to ensure ... and 3D LiDAR. , A Safe Space™ enabled business will provide a ...
Breaking Biology Technology: